Japanese drug major Astellas Pharma (TYO: 4503) has appointed Eric Terhaerdt as senior vice president of global development operations.
He will be responsible for establishing the global direction of the drug development operations of Astellas in the Netherlands and the USA and will work with Japan development operations to ensure global ops efficiency.
He will define development strategy and ensure the effective development of the company’s product portfolio.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze